| Pneumococcus, purified polysaccharides antigen |
II- 15385/28.12.2006 г. |
Pneumo 23, Powder and solvent for suspension for injection, 0.5, ml, Pack: 1 |
Sanofi Pasteur S.A., Франция |
Sanofi Pasteur S.A., France |
17.68 |
3.54 |
21.22 |
6% |
1.06 |
18.74 |
3.75 |
22.49 |
18% |
3.18 |
21.92 |
4.38 |
26.3 |
|
КЦ-1068/30.07.2009 |
14.08.2009 |
Неактивен |
1955 |
| Linezolid |
20140117 |
Pneumolid, Solution for infusion, 2 mg/ml - 300 ml, mg, Pack: 1 |
Alvogen IPCo S.àr.l, Люксембург |
Synthon BV, Нидерландия; Synthon Hispania S.L., Испания |
45.26 |
9.05 |
54.31 |
4% |
1.81 |
47.07 |
9.41 |
56.48 |
16% |
7.24 |
54.31 |
10.86 |
65.17 |
|
НСР-7223/15.10.2015. |
30.10.2015 |
Активен |
3009 |
| Linezolid |
20140117 |
Pneumolid, Solution for infusion, 2 mg/ml - 300 ml, mg, Pack: 1 |
Alvogen IPCo S.àr.l, Люксембург |
Synthon BV, Нидерландия; Synthon Hispania S.L., Испания |
57.05 |
11.41 |
68.46 |
4% |
2.28 |
59.33 |
11.87 |
71.2 |
16% |
9.13 |
68.46 |
13.69 |
82.15 |
|
НСР-4021/03.07.2014 |
18.07.2014 |
Неактивен |
3009 |
| Poliomyelitis vaccine, inactivated |
II-10716 / 25.04.2005 г. |
Poliorix, Solution for injection, 0.5ml (1dose), -, Pack: 1 vial |
GlaxoSmithKline Biologicals S.A., Белгия |
GlaxoSmithKline Biologicals, rue de l'Institut 89, 1330 Rixensart, Belgium |
13.73 |
2.75 |
16.48 |
6% |
0.82 |
14.55 |
2.91 |
17.46 |
18% |
2.47 |
17.02 |
3.4 |
20.42 |
|
КЦ-262/27.10.2008 |
18.11.2008 |
Активен |
128 |
| Poliomyelitis vaccine, (live attenuated) |
II-15207/12.12.2006 г. |
POLIO SABIN (ORAL), Oral drops, suspension, 10 doses (1 ml), -, Pack: 100 vial + dropper applicator |
ГлаксоСмитКлайн ЕООД, България |
GlaxoSmithKline Biologicals, rue de l'Institut 89, 1330 Rixensart, Belgium |
655.2 |
131.04 |
786.24 |
4% |
10 |
665.2 |
133.04 |
798.24 |
16% |
25 |
690.2 |
138.04 |
828.24 |
|
КЦ-773/02.04.2009 |
06.05.2009 |
Активен |
687 |
| Memantine |
20130396 |
Polmatine, Film‐coated tablet, 10, mg, Pack: 28 |
Medana Pharma S.A., Полша |
Pharmaceutical Works POLPHARMA S.A.,Полша |
47.35 |
9.47 |
56.82 |
4% |
1.89 |
49.24 |
9.85 |
59.09 |
16% |
7.58 |
56.82 |
11.36 |
68.18 |
|
НСР-6503/18.06.2015 |
04.07.2015 |
Активен |
2562 |
| Memantine |
20130396 |
Polmatine, Film‐coated tablet, 10, mg, Pack: 28 |
Medana Pharma S.A., Полша |
Pharmaceutical Works POLPHARMA S.A.,Полша |
54 |
10.8 |
64.8 |
4% |
2.16 |
56.16 |
11.23 |
67.39 |
16% |
8.64 |
64.8 |
12.96 |
77.76 |
|
НСР-2908/05.03.2014 |
20.03.2014 |
Неактивен |
2562 |
| Memantine |
20130398 |
Polmatine, Oral solution, 5 mg/pump actuation/- 50ml, mg, Pack: 1 |
Medana Pharma S.A., Полша |
Medana Pharma SA, Полша |
90.01 |
18 |
108.01 |
4% |
3.6 |
93.61 |
18.72 |
112.33 |
16% |
14.4 |
108.01 |
21.6 |
129.61 |
|
НСР-3029/21.03.2013 |
09.04.2014 |
Активен |
2611 |
| Technetium (99mTc) pertechnetate |
20150115 |
Poltechnet 8,0 - 175 GBq, radionuclide generator, 7,5 GBq, GBq, Pack: 1 |
National Centre for Nuclear Research, Полша, Полша |
National Centre for Nuclear Research, Полша; I.R.E. (Institut National des Radioéléments), Белгия; NTP Radioisotopes SOC Ltd., ЮАР |
1157.85 |
231.57 |
1389.42 |
4% |
10 |
1167.85 |
233.57 |
1401.42 |
16% |
25 |
1192.85 |
238.57 |
1431.42 |
|
НСР-7353/05.11.2015. и НСР-7500/13.11.2015. (допуска се предварително изпълнение) |
13.11.2015 |
Активен |
4103 |
| Technetium (99mTc) pertechnetate |
20150115 |
Poltechnet 8,0 - 175 GBq, radionuclide generator, 12,5 GBq, GBq, Pack: 1 |
National Centre for Nuclear Research, Полша, Полша |
National Centre for Nuclear Research, Полша; I.R.E. (Institut National des Radioéléments), Белгия; NTP Radioisotopes SOC Ltd., ЮАР |
1488.39 |
297.68 |
1786.07 |
4% |
10 |
1498.39 |
299.68 |
1798.07 |
16% |
25 |
1523.39 |
304.68 |
1828.07 |
|
НСР-7353/05.11.2015. и НСР-7500/13.11.2015. (допуска се предварително изпълнение) |
13.11.2015 |
Активен |
4104 |
| Perindopril, Indapamide |
20110360 |
Pontea, Film‐coated tablet, 4 mg/ 1,25 mg, mg, Pack: 30 |
Stada Arzneimittel AG, Германия |
Glenmark Pharmaceutical Ltd – UK; Glenmark Pharmaceutical sro – Czech Republic |
6.2 |
1.24 |
7.44 |
7% |
0.43 |
6.63 |
1.33 |
7.96 |
20% |
1.24 |
7.87 |
1.57 |
9.44 |
|
НСР-6149/29.04.2015. |
14.05.2015 |
Активен |
3864 |
| Perindopril, Indapamide |
20110359 |
Pontea, Film‐coated tablet, 2 mg/ 0,625 mg, mg, Pack: 30 |
Stada Arzneimittel AG, Германия |
Glenmark Pharmaceutical Ltd – UK; Glenmark Pharmaceutical sro – Czech Rep. |
3.64 |
0.73 |
4.37 |
7% |
0.25 |
3.89 |
0.78 |
4.67 |
20% |
0.73 |
4.62 |
0.92 |
5.54 |
|
НСР-2504/24.01.2014 |
14.02.2014 |
Активен |
2479 |
| Perindopril, Indapamide |
20110360 |
Pontea, Film‐coated tablet, 4 mg/ 1,25 mg, mg, Pack: 30 |
Stada Arzneimittel AG, Германия |
Glenmark Pharmaceutical Ltd – UK; Glenmark Pharmaceutical sro – Czech Rep |
7.53 |
1.51 |
9.04 |
7% |
0.53 |
8.06 |
1.61 |
9.67 |
20% |
1.51 |
9.57 |
1.91 |
11.48 |
|
НСР-2505/24.01.2014 |
14.02.2014 |
Неактивен |
3864 |
| Perindopril, Indapamide |
20110360 |
Pontea, Film‐coated tablet, 4 mg/ 1,25 mg, mg, Pack: 30 |
Stada Arzneimittel AG, Германия |
Glenmark Pharmaceutical Ltd – UK; Glenmark Pharmaceutical sro – Czech Rep |
7.78 |
1.56 |
9.34 |
7% |
0.54 |
8.32 |
1.66 |
9.98 |
20% |
1.56 |
9.88 |
1.98 |
11.86 |
|
КЦРР-1358/05.09.2012 |
02.10.2012 |
Неактивен |
3864 |
| Perindopril, Indapamide |
20110359 |
Pontea, Film‐coated tablet, 2 mg/ 0,625 mg, mg, Pack: 30 |
Stada Arzneimittel AG, Германия |
Glenmark Pharmaceutical Ltd – UK; Glenmark Pharmaceutical sro – Czech Rep. |
4.79 |
0.96 |
5.75 |
7% |
0.34 |
5.13 |
1.03 |
6.16 |
20% |
0.96 |
6.09 |
1.22 |
7.31 |
|
КЦРР-1227/13.08.2012 |
14.09.2012 |
Неактивен |
2479 |
| Topotecan |
EU/1/10/660/002 |
POTACTASOL, Powder for concentrate for solution for infusion, 4, mg, Pack: 1 |
Actavis Group PTC ehf., Исландия |
S.C. Sindann-Pharma S.R.L., Romania |
59.4 |
11.88 |
71.28 |
4% |
2.38 |
61.78 |
12.36 |
74.14 |
16% |
9.5 |
71.28 |
14.26 |
85.54 |
|
НСР-3817/16.06.2014 |
01.07.2014 |
Активен |
2969 |
| Topotecan |
EU/1/10/660/002 |
POTACTASOL, Powder for concentrate for solution for infusion, 4, mg, Pack: 1 |
Actavis Group PTC ehf., Исландия |
S.C. Sindann-Pharma S.R.L., Romania |
153.61 |
30.72 |
184.33 |
4% |
6.14 |
159.75 |
31.95 |
191.7 |
16% |
24.58 |
184.33 |
36.87 |
221.2 |
|
КЦРР-2961/20.03.2013 |
24.04.2013 |
Неактивен |
2969 |
| Topotecan |
EU/1/10/660/002 |
POTACTASOL, Powder for concentrate for solution for infusion, 4, mg, Pack: 1 |
Actavis Group PTC ehf., Исландия |
S.C. Sindann-Pharma S.R.L., Romania |
284.24 |
56.85 |
341.09 |
4% |
10 |
294.24 |
58.85 |
353.09 |
16% |
25 |
319.24 |
63.85 |
383.09 |
|
КЦ-2433/06.07.2011 |
26.07.2011 |
Неактивен |
2969 |
| Tuberculini purified Protein Derivative for human use |
20000719 |
PPD Tuberculin Mammalian, Solution for injection, 5 TU/0.1 ml - 1 ml, -, Pack: x 10 флакони (10 дози) |
БУЛ БИО-НЦЗПБ ЕООД, България |
БУЛ БИО -НЦЗПБ ЕООД, София, България |
66 |
13.2 |
79.2 |
4% |
2.64 |
68.64 |
13.73 |
82.37 |
16% |
10.56 |
79.2 |
15.84 |
95.04 |
|
НСР-9381/01.06.2016 |
02.07.2016 |
Активен |
15138 |
| Tuberculini purified Protein Derivative for human use |
0995/05.11.2007 г. |
PPD Tuberculin Mammalian, Solution for injection, 5 TU/0,1 ml, -, Pack: 1 fl. x 1 ml (10 doses) |
БУЛ БИО-НЦЗПБ ЕООД, България |
БУЛ БИО-НЦЗПБ ЕООД |
35 |
7 |
42 |
4% |
1.4 |
36.4 |
7.28 |
43.68 |
16% |
5.6 |
42 |
8.4 |
50.4 |
протокол № 174/19.05.2016 |
КЦ-117/23.06.2008 |
39652 |
Активен |
66 |
| Tuberculini purified Protein Derivative for human use |
0995/05.11.2007 г. |
PPD Tuberculin Mammalian, Solution for injection, 5 TU/0,1 ml, -, Pack: 10 ampoules |
БУЛ БИО-НЦЗПБ ЕООД, България |
БУЛ БИО-НЦЗПБ ЕООД |
35 |
7 |
42 |
4% |
1.4 |
36.4 |
7.28 |
43.68 |
16% |
5.6 |
42 |
8.4 |
50.4 |
|
КЦ-117/23.06.2008 |
23.07.2008 |
Неактивен |
66 |
| Dabigatran etexilate |
EU/1/08/442/011 |
PRADAXA, Capsule, hard, 150, mg, Pack: 60 |
Boehringer Ingelheim International GmbH, Германия |
Boehringer Ingelheim Pharma GmbH & Co. KG, Germany |
111.99 |
22.4 |
134.39 |
4% |
4.48 |
116.47 |
23.29 |
139.76 |
16% |
17.92 |
134.39 |
26.88 |
161.27 |
|
НСР-7654/01.12.2015. |
16.12.2015 |
Активен |
2546 |
| Dabigatran etexilate |
EU/1/08/442/011 |
PRADAXA, Capsule, hard, 150, mg, Pack: 60 |
Boehringer Ingelheim International GmbH, Германия |
Boehringer Ingelheim Pharma GmbH & Co. KG, Germany |
113.83 |
22.77 |
136.6 |
4% |
4.55 |
118.38 |
23.68 |
142.06 |
16% |
18.21 |
136.59 |
27.32 |
163.91 |
|
НСР-2857/21.02.2014 |
10.03.2014 |
Неактивен |
2546 |
| Dabigatran etexilate |
EU/1/08/442/011 |
PRADAXA, Capsule, hard, 150, mg, Pack: 60 |
Boehringer Ingelheim International GmbH, Германия |
Boehringer Ingelheim Pharma GmbH & Co. KG, Germany |
117.35 |
23.47 |
140.82 |
4% |
4.69 |
122.04 |
24.41 |
146.45 |
16% |
18.78 |
140.82 |
28.16 |
168.98 |
|
HCР-285/28.06.2013. |
16.07.2013 |
Неактивен |
2546 |
| Dabigatran etexilate |
EU/1/08/442/011 |
PRADAXA, Capsule, hard, 150, mg, Pack: 60 |
Boehringer Ingelheim International GmbH, Германия |
Boehringer Ingelheim Pharma GmbH & Co. KG, Germany |
134.95 |
26.99 |
161.94 |
4% |
5.4 |
140.35 |
28.07 |
168.42 |
16% |
21.59 |
161.94 |
32.39 |
194.33 |
|
КЦ-2710/13.09.2011 |
27.09.2011 |
Неактивен |
2546 |